

Dorota Kozielowicz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9408215/publications.pdf>

Version: 2024-02-01

19
papers

335
citations

759233

12
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

407
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations of management in SARS-CoV-2 infection of the Polish Association of Epidemiologists and Infectiologists. Polish Archives of Internal Medicine, 2020, 130, 352-357.	0.4	51
2	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. Polish Archives of Internal Medicine, 2021, 131, 487-496.	0.4	48
3	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 2 as of October 13, 2020. Polish Archives of Internal Medicine, 2020, 130, 915-918.	0.4	30
4	Effectiveness and safety of ledipasvir/sofosbuvir ± ribavirin in the treatment of HCV infection: The real-world HARVEST study. Advances in Medical Sciences, 2017, 62, 387-392.	2.1	23
5	Convalescent Plasma Transfusion for the Treatment of COVID-19 – Experience from Poland: A Multicenter Study. Journal of Clinical Medicine, 2021, 10, 28.	2.4	23
6	Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. Journal of Clinical Medicine, 2021, 10, 1583.	2.4	21
7	Annex #1 as of 8 June 2020 to: Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020. Polish Archives of Internal Medicine, 2020, 130, 557-558.	0.4	20
8	The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland. Environmental Pollution, 2022, 306, 119469.	7.5	20
9	Prophylaxis of vertical HBV infection. Expert Opinion on Drug Safety, 2016, 15, 1361-1368.	2.4	18
10	Demographic and Clinical Overview of Hospitalized COVID-19 Patients during the First 17 Months of the Pandemic in Poland. Journal of Clinical Medicine, 2022, 11, 117.	2.4	18
11	Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study. Journal of Inflammation Research, 2021, Volume 14, 3359-3366.	3.5	17
12	The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C. PLoS ONE, 2015, 10, e0130899.	2.5	13
13	Impact of Kidney Failure on the Severity of COVID-19. Journal of Clinical Medicine, 2021, 10, 2042.	2.4	13
14	Diagnosis and therapy of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of November 12, 2021. Annex no. 1 to the Recommendations of April 26, 2021. Polish Archives of Internal Medicine, 2021, 131, .	0.4	6
15	Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta. Neurologia I Neurochirurgia Polska, 2015, 49, 451-455.	1.2	5
16	Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment. Hepatology International, 2016, 10, 302-309.	4.2	3
17	Efficacy and safety of pegylated interferon ± and ribavirin in patients monoinfected with HCV genotype 4. Przegląd Gastroenterologiczny, 2018, 13, 22-29.	0.7	3
18	Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors. Expert Opinion on Drug Safety, 2015, 14, 1815-1825.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Long-term outcomes of thyroid dysfunction in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. <i>Przegląd Epidemiologiczny</i> , 2017, 71, 555-569.	0.2	1